BioCentury on BioBusiness,
So who's responsible?
Monday, January 13, 1997
Do biotech prices surge simply because a conference exists? Should last week's trading be attributed to the Hambrecht & Quist Healthcare Conference? Or should it simply be ascribed to the January Effect - a scenario in which portfolio managers start the year anew, and are more receptive to growth stories in an effort to begin the year off with a bang. One argument for H&Q influence is that most of the presenting companies at last week's conference in San Francisco received price bumps, while the BioCentury 100 closed up only 1 percent at 1245.36.
H&Q banker Dennis Purcell, in a luncheon address on Tuesday, pointed out that the biotech sector had enough momentum on Monday to rise despite a tepid broad market. While the broad markets were mixed on Monday, "with half the stocks closing down and half the stocks closing up," Purcell noted, "85 percent of the
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]